Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: A retrospective study

British Journal of Cancer

Volumn 94, Issue 7, 2006, Pages 1016-1020

  Bengala, C ^a   Zamagni, C ^b   Pedrazzoli, P ^c   Matteucci, P ^d   Ballestrero, A ^e   Da Prada, G ^f   Martino, M ^g   Rosti, G ^h   Danova, M ⁱ   Bregni, M ^j   Jovic, G ^a   Guarneri, V ^a   Maur, M ^a   Conte, P F ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f Maugeri Cancer Foundation   (Italy)

^g Civic Hospital   (Italy)

^h Civic Hospital   (Italy)

ⁱ University and Research Hospital   (Italy)

^j SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

Cardiac toxicity; High dose chemotherapy; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; MELPHALAN; MITOXANTRONE; NAVELBINE; PACLITAXEL; THIOTEPA; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 33645748115     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603060     Document Type: Article

References (29)

1. Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH, Czuzman MS, Slack JL, Spangenthal E, Wetzler M, Barcos MP, Proulx GM, Anderson B, McCarthy Jr PL (1999) Thiotepa-associated cardiomiopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biol Blood Marrow Transplant 5: 322-327
2. Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF (2003) High-dose consolidation chemotherapy with idarubicin and alkylating agents following induction with gemcitabine - epirubicin - paclitaxel in metastatic breast cancer: a dose finding study. Bone Marrow Transplant 31: 275-280
3. Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, Guarneri V, Del Tacca M, Conte PF (2001) High-dose thiotepa and melphalan with hempoietic progenitor support following induction therapy with epirubicin - paclitaxel - containing regimens in metastatic breast cancer (MBC). Ann Oncol 12: 69-74
4. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized trial of Scandinavian Breast Group 9401 study. Lancet 356: 1384-1391
5. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J (1996) Her2/neu overxpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (> 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 2: 1509-1513
6. Crown JP, Leyvraz S, Verrill M, Guillem V, Efremidis A, Garcia-Conde Bru J, Welch R, Montes A, Leonard R, Baselga J (2004) Effect of tandem high-dose chemotherapy on long-term complete remission in metastatic breast cancer compared to conventional dose in patients who were not selected on basis of response to prior chemotherapy: mature results of the IBDIS-1. Proc Am Soc Clin Oncol 23: 34 (Abstr. 631).
7. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF (1999) Cardiotoxicity of epirubicin/ paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 17: 3596-3602
8. Goncalves A, Braud AC, Viret F, Tarpin C, Charaffe-Jauffret E, Jacquemier J, Maraninchi D, Viens P (2005) High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overxpressing metastatic breast cancer: a feasibility study. Anticancer Res 25: 663-668
9. Guarneri V, Bengala C, Orlandini C, Gennari A, Donati S, Campani D, Collecchi P, Maur M, Conte PF (2004) HER2 overxpression as prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone Marrow Transplant 34: 413-417
10. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE (2000) Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92: 225-233
11. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT (2001) HER2 overxpression as poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7: 4008-4012
12. Lotz JP, Cure H, Janvier M, Asselain B, Morvan F, Legros M, Audhuy B, Biron P, Guillemot M, Goubet J, Laadem A, Cailliot C, Maignan CL, Delozier T, Glaisner S, Maraninchi D, Roche H, Gisselbrecht C (2005) High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomized CMA/PEGASE 04 protocol. Eur J Cancer 41: 71-80
13. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patient with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23: 4265-4274
14. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V (2005) Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 35: 323-334
15. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB (2000) Cardiac toxicity following high-dose cyclophosphamide, cisplatin and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 6: 198-203
16. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Baron A, Razook C, Matthes S, Bearman SI (2002) Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20: 707-718
17. Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Chao N, Rizzieri D, Gasparetto C, Matthes S, Baron AE, Jones RB (2004) Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res 10: 7136-7143
18. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schutt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rosel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M, West German Study Group (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366: 1935-1944
19. Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22: 322-329
20. Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP (2002) Association of high-dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with survival, toxicity and dosing weight in patients with primary breast cancer. Clin Cancer Res 8: 698-705
21. Roche H, Viens P, Biron P, Lotz JP, Asselain B, PEGASE Group (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10: 42-47
22. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG, Netherlands Working Party on Autologous Transplantation in Solid Tumors (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349: 7-16
23. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M, Possinger K (2005) Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23: 432-440
24. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
26. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
27. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer: Philadelphia Bone Marrow Group. N Engl J Med 342: 1069-1076
28. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349: 17-26
29. Tan-Chiu E, Yothers G, Romond E, Geyer Jr CE, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23: 7811-7819